Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target boosted by equities researchers at JPMorgan Chase & Co. from $272.00 to $280.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 15.50% from the company’s previous close.

ALNY has been the topic of a number of other reports. Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Finally, Scotiabank dropped their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Stock Up 1.5 %

Shares of ALNY opened at $242.43 on Tuesday. The stock has a market capitalization of $31.38 billion, a PE ratio of -111.72 and a beta of 0.39. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company’s 50-day simple moving average is $254.71 and its 200-day simple moving average is $260.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last three months. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bannerman Wealth Management Group LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $327,000. Siemens Fonds Invest GmbH increased its position in shares of Alnylam Pharmaceuticals by 137.7% in the fourth quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company’s stock valued at $764,000 after buying an additional 1,880 shares in the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $28,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $29,263,000. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $637,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.